Page 248 - Read Online

Page 10 of 10 Raevsky et al. Neuroimmunol Neuroinflammation 2018;5:33 I http://dx.doi.org/10.20517/2347-8659.2018.34

21. Katunuma N. Structure-based development of specific inhibitors for individual cathepsins and their medical applications. Proc Jpn Acad
Ser B Phys Biol Sci 2011;87:29-39.
22. Smith HJ, Simons C. Protease and peptidase inhibition: recent potential targets for drug development. London: CRC Press; 2002. p. 94-
144.
23. Suzuki K, Hata S, Kawabata Y, Sorimachi H. Structure, activation, and biology of calpain. Diabetes 2004;53 Suppl 1:S12-8.
24. Frlan R, Gobec S. Inhibitors of cathepsin B. Curr Med Chem 2006;13:2309-27.
25. Ito H, Watanabe M, Kim YT, Takahashi K. Inhibition of rat liver cathepsins B and L by the peptide aldehyde benzyloxycarbonyl-leucyl-
leucyl-leucinal and its analogues. J Enzyme Inhib Med Chem 2009;24:279-86.
26. Schaschke N, Deluca D, Assfalg-Machleidt I, Hohneke C, Sommerhoff CP, Machleidt W. Epoxysuccinyl peptide-derived cathepsin
B inhibitors: Modulating membrane permeability by conjugation with the C-terminal heptapeptide segment of penetratin. Biol Chem
2002;383:849-52.
27. Quesne MG, Ward RA, de Visser SP. Cysteine protease inhibition by nitrile-based inhibitors: a computational study. Front Chem
2013;1:39.
28. Ramalho SD, de Sousa LR, Burger MC, Lima MI, da Silva MF, Fernandes JB, Vieira PC. Evaluation of flavonols and derivatives as hu-
man cathepsin B inhibitor. Nat Prod Res 2015;29:2212-4.
29. Gunatilleke SS, Barrios AM. Inhibition of lysosomal cysteine proteases by a series of Au(I) complexes: a detailed mechanistic investi-
gation. J Med Chem 2006;49:3933-7.
30. Berners-Price SJ. Gold-based therapeutic agents: a new perspective. In Alessio E (Ed.). Bioinorganic medicinal chemistry. John Wiley
& Sons, Weinheim. 2011. p. 197-222.
31. Gunatilleke SS, de Oliveira CA, McCammon JA, Barrios AM. Inhibition of cathepsin B by Au(I) complexes: a kinetic and computa-
tional study. J Biol Inorg Chem 2008;13:555-61.
32. Case DA, Darden TA, Cheatham TE, Simmerling CL, Wang J, Duke RE. AMBER 12. University of California, San Francisco, USA
2012.
33. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE. The protein data bank. Nucleic Acids
Res 2000;28:235-42.
34. Pronk S, Páll S, Schulz R, Larsson P, Bjelkmar P, Apostolov R, Shirts MR, Smith JC, Kasson PM, van der Spoel D, Hess B, Lindahl E.
GROMACS 4.5: a high-throughput and highly parallel open source molecular simulation toolkit. Bioinformatics 2013;29:845-54.
35. Jain AN. Surflex-Dock 2.1: Robust performance from ligand energetic modeling, ring flexibility, and knowledge-based search. J Com-
put Aided Mol Des 2007;21:281-306.
36. Gunatilleke SS. Inhibition of csteine proteases by gold(I) complexes: A kinetic and mechanistic investigation. PhD Dissertation, Univer-
sity of Southern California. http://digitallibrary.usc.edu/cdm/ref/collection/p15799coll127/id/529088. [Last accessed on 8 Aug 2018]
37. Hulkower KI, Butler CC, Linebaugh BE, Klaus JL, Keppler D, Giranda VL, Sloane BF. Fluorescent microplate assay for cancer cell-
associated cathepsin B. Eur J Biochem 2000;267:4165-70.
38. Greenspan PD, Clark KL, Tommasi RA, Cowen SD, McQuire LW, Farley DL, van Duzer JH, Goldberg RL, Zhou H, Du Z, Fitt JJ,
Coppa DE, Fang Z, Macchia W, Zhu L, Capparelli MP, Goldstein R, Wigg AM, Doughty JR, Bohacek RS, Knap AK. Identification of
dipeptidyl nitriles as potent and selective inhibitors of cathepsin B through structure-based drug design. J Med Chem 2001;44:4524-34.
39. Bento AP, Gaulton A, Hersey A, Bellis LJ, Chambers J, Davies M, Krüger FA, Light Y, Mak L, McGlinchey S, Nowotka M, Papadatos G,
Santos R, Overington JP. The ChEMBL bioactivity database: an update. Nucleic Acids Res 2014;42:D1083-90.
40. Jones PG, Maddock AG, Mays MJ, Muir MM, Williams AF. Structure and bonding in gold(I) compounds. Part 2. Mössbauer spectrum
of linear gold(I) complexes. J Chem Soc Dalton Trans 1977;15:1434-9.
41. Madeira JM, Gibson DL, Kean WF, Klegeris A. The biological activity of auranofin: implications for novel treatment of diseases. Inflam-
mopharmacology 2012;20:297-306.
42. Madeira JM, Schindler SM, Klegeris A. A new look at auranofin, dextromethorphan and rosiglitazone for reduction of glia-mediated in-
flammation in neurodegenerative diseases. Neural Regen Res 2015;10:391-3.
43. Lowry JR, Klegeris A. Emerging roles of microglial cathepsins in neurodegenerative disease. Brain Res Bull 2018;139:144-56.